We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside
Key Takeaways
ISRG, the undisputed leader in surgical robotics, is down 30% from its 2025 highs.
The Zacks Rank #2 (Buy) stock is poised for a technical breakout heading into its Q3 earnings release.
Intuitive's pristine debt-free balance sheet empowers it to adapt and expand.
Intuitive Surgical, Inc. (ISRG - Free Report) , the medical technology giant and the undisputed leader in surgical robotics, has fallen 30% from its early 2025 highs.
The selloff and its strong fundamentals, including a double-digit earnings and revenue growth outlook and impressive free cash flow expansion, make ISRG stock a great buy-and-hold candidate right now, especially as Wall Street keeps selling AI stocks.
ISRG stock surged off its recent lows heading into its Q3 earnings release that’s due out after the closing bell on Tuesday, October 20.
Intuitive Surgical stock earns a Zacks Rank #2 (Buy) and looks poised for a potential technical breakout as it overtakes vital long-term levels.
Image Source: Zacks Investment Research
The firm’s pristine debt-free balance sheet empowers Intuitive Surgical to adapt and expand into any number of growth areas.
All in, investors looking to diversify beyond tumbling AI stocks should consider buying the da Vinci robotic surgery systems maker for ~40% upside if it ever returns to its all-time highs.
Looking for S&P 500 Stocks to Buy On the Dip in Q3 Earnings Season? Buy ISRG
Intuitive Surgical helped kick off the Sci-Fi age of healthcare when its da Vinci Surgical System was first cleared by the FDA in 1997 to assist in surgery and to perform actual surgery in 2000. Since then, its da Vinci robotic surgery systems have become integral throughout an array of procedures across urology, general surgery, gynecology, and beyond.
ISRG’s robots give surgeons better control, vision, and precision through small incisions, which can mean less pain, smaller scars, and faster recovery for patients compared with traditional open surgery.
The firm boasts that its technologies have performed 20.4 million+ procedures since it launched (as of Dec. 2025), including 3.2 million+ procedures performed on Intuitive systems in 2025.
Image Source: Zacks Investment Research
The S&P 500 medical technology company is making progress in vital surgical areas such as Thoracic (chest/lung surgery), Cardiac, Head and neck, and more.
The company also makes a robotic system for lung biopsies (not surgery) called the Ion. It helps doctors reach and sample small, hard-to-reach nodules deep in the lungs to check for cancer or other issues.
Intuitive Surgical’s rise sparked competition from Medtronic, Johnson & Johnson (JNJ - Free Report) , and others. But its growth outlook remains impressive after 25 years of expansion, and its offerings are only gaining in popularity as the healthcare world races to embrace as much cutting-edge technology as possible.
Buy ISRG Stock for Earnings and Sales Growth
ISRG more than doubled its revenue between 2020 and 2025. It grew its sales by 21% in 2025, marking its strongest YoY expansion since 2021. The surgical robotics firm also doubled its GAAP earnings between the pre-Covid period in 2019 and 2025, boosted by 29% average expansion over the past three years.
In the near term, Intuitive Surgical is projected to grow its Q3 revenue by 15% to $2.88 billion. The company is projected to grow its adjusted quarterly earnings by 9% YoY to $2.61 a share.
ISRG beat our Zacks bottom-line estimate by an average of 17% in the past four quarters. Its upbeat EPS revisions for 2027 help it earn a Zacks Rank #2 (Buy) right now.
Image Source: Zacks Investment Research
It is projected to grow its revenue by 17% in 2026 and 13% next year to reach $13.21 billion, doubling 2022’s total in the process.
ISRG is expected to grow its adjusted earnings by over 20% in 2026 and 12% next year. The chart below showcases that its long-term earnings growth outlook over the next several years remains impressive.
Image Source: Zacks Investment Research
Why ISRG is One of the Best Stocks to Buy Now for Big Upside
ISRG stock has climbed by a mind-blowing ~20,800% in the past 25 years, including a ~790% charge in the last 15 to crush its industry’s 300%.
Yet it has lagged the S&P 500 over the last five years on the back of its ~30% fall from its early 2025 highs.
This backdrop alone means that Intuitive Surgical offers roughly 43% upside if it ever returns to its all-time highs. The stock already climbed 30% from its July lows after buyers stepped in and held their ground near its previous 2021 highs.
ISRG is on the cusp of overtaking its 200-day. More importantly, Intuitive Surgical stock is back above its critical long-term 200-week moving average.
Image Source: Zacks Investment Research
One thing holding the stock back appears to be its valuation, with it trading at 43.7X forward 12-month earnings. This marks a huge premium compared to its industry’s 27.9X. But it has crushed its peers over the last 10 years, up ~470% vs. 112%. Plus, ISRG is trading at a 53% discount to its highs.
If Wall Street continues to reject its valuation levels as its growth slows, Intuitive Surgical could easily start paying a dividend to reward investors, given its debt-free balance sheet and growing cash position.
View the Zacks #1 Rank List
Image: Bigstock
Forget AI Stocks: Buy Med-Tech Stock ISRG Now for 40% Upside
Key Takeaways
Intuitive Surgical, Inc. (ISRG - Free Report) , the medical technology giant and the undisputed leader in surgical robotics, has fallen 30% from its early 2025 highs.
The selloff and its strong fundamentals, including a double-digit earnings and revenue growth outlook and impressive free cash flow expansion, make ISRG stock a great buy-and-hold candidate right now, especially as Wall Street keeps selling AI stocks.
ISRG stock surged off its recent lows heading into its Q3 earnings release that’s due out after the closing bell on Tuesday, October 20.
Intuitive Surgical stock earns a Zacks Rank #2 (Buy) and looks poised for a potential technical breakout as it overtakes vital long-term levels.
Image Source: Zacks Investment Research
The firm’s pristine debt-free balance sheet empowers Intuitive Surgical to adapt and expand into any number of growth areas.
All in, investors looking to diversify beyond tumbling AI stocks should consider buying the da Vinci robotic surgery systems maker for ~40% upside if it ever returns to its all-time highs.
Looking for S&P 500 Stocks to Buy On the Dip in Q3 Earnings Season? Buy ISRG
Intuitive Surgical helped kick off the Sci-Fi age of healthcare when its da Vinci Surgical System was first cleared by the FDA in 1997 to assist in surgery and to perform actual surgery in 2000. Since then, its da Vinci robotic surgery systems have become integral throughout an array of procedures across urology, general surgery, gynecology, and beyond.
ISRG’s robots give surgeons better control, vision, and precision through small incisions, which can mean less pain, smaller scars, and faster recovery for patients compared with traditional open surgery.
The firm boasts that its technologies have performed 20.4 million+ procedures since it launched (as of Dec. 2025), including 3.2 million+ procedures performed on Intuitive systems in 2025.
Image Source: Zacks Investment Research
The S&P 500 medical technology company is making progress in vital surgical areas such as Thoracic (chest/lung surgery), Cardiac, Head and neck, and more.
The company also makes a robotic system for lung biopsies (not surgery) called the Ion. It helps doctors reach and sample small, hard-to-reach nodules deep in the lungs to check for cancer or other issues.
Intuitive Surgical’s rise sparked competition from Medtronic, Johnson & Johnson (JNJ - Free Report) , and others. But its growth outlook remains impressive after 25 years of expansion, and its offerings are only gaining in popularity as the healthcare world races to embrace as much cutting-edge technology as possible.
Buy ISRG Stock for Earnings and Sales Growth
ISRG more than doubled its revenue between 2020 and 2025. It grew its sales by 21% in 2025, marking its strongest YoY expansion since 2021. The surgical robotics firm also doubled its GAAP earnings between the pre-Covid period in 2019 and 2025, boosted by 29% average expansion over the past three years.
In the near term, Intuitive Surgical is projected to grow its Q3 revenue by 15% to $2.88 billion. The company is projected to grow its adjusted quarterly earnings by 9% YoY to $2.61 a share.
ISRG beat our Zacks bottom-line estimate by an average of 17% in the past four quarters. Its upbeat EPS revisions for 2027 help it earn a Zacks Rank #2 (Buy) right now.
Image Source: Zacks Investment Research
It is projected to grow its revenue by 17% in 2026 and 13% next year to reach $13.21 billion, doubling 2022’s total in the process.
ISRG is expected to grow its adjusted earnings by over 20% in 2026 and 12% next year. The chart below showcases that its long-term earnings growth outlook over the next several years remains impressive.
Image Source: Zacks Investment Research
Why ISRG is One of the Best Stocks to Buy Now for Big Upside
ISRG stock has climbed by a mind-blowing ~20,800% in the past 25 years, including a ~790% charge in the last 15 to crush its industry’s 300%.
Yet it has lagged the S&P 500 over the last five years on the back of its ~30% fall from its early 2025 highs.
This backdrop alone means that Intuitive Surgical offers roughly 43% upside if it ever returns to its all-time highs. The stock already climbed 30% from its July lows after buyers stepped in and held their ground near its previous 2021 highs.
ISRG is on the cusp of overtaking its 200-day. More importantly, Intuitive Surgical stock is back above its critical long-term 200-week moving average.
Image Source: Zacks Investment Research
One thing holding the stock back appears to be its valuation, with it trading at 43.7X forward 12-month earnings. This marks a huge premium compared to its industry’s 27.9X. But it has crushed its peers over the last 10 years, up ~470% vs. 112%. Plus, ISRG is trading at a 53% discount to its highs.
If Wall Street continues to reject its valuation levels as its growth slows, Intuitive Surgical could easily start paying a dividend to reward investors, given its debt-free balance sheet and growing cash position.